HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.1368
https://www.valueinhealthjournal.com/article/S1098-3015(24)01483-9/fulltext
Title :
HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)01483-9&doi=10.1016/j.jval.2024.03.1368
First page :
Section Title :
Open access? :
No
Section Order :
10756